446 related articles for article (PubMed ID: 30517165)
1. Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review.
Grochtdreis T; König HH; Dobruschkin A; von Amsberg G; Dams J
PLoS One; 2018; 13(12):e0208063. PubMed ID: 30517165
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance.
Barqawi YK; Borrego ME; Roberts MH; Abraham I
J Med Econ; 2019 Nov; 22(11):1202-1209. PubMed ID: 31452414
[No Abstract] [Full Text] [Related]
3. Cost-effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer.
Gong CL; Hay JW
J Natl Compr Canc Netw; 2014 Oct; 12(10):1417-25. PubMed ID: 25313181
[TBL] [Abstract][Full Text] [Related]
4. New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions?
Wilson L; Tang J; Zhong L; Balani G; Gipson G; Xiang P; Yu D; Srinivas S
J Oncol Pharm Pract; 2014 Dec; 20(6):417-25. PubMed ID: 24243919
[TBL] [Abstract][Full Text] [Related]
5. Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence.
Norum J; Nieder C
Pharmacoeconomics; 2017 Dec; 35(12):1223-1236. PubMed ID: 28756597
[TBL] [Abstract][Full Text] [Related]
6. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer.
Collins R; Fenwick E; Trowman R; Perard R; Norman G; Light K; Birtle A; Palmer S; Riemsma R
Health Technol Assess; 2007 Jan; 11(2):iii-iv, xv-xviii, 1-179. PubMed ID: 17181985
[TBL] [Abstract][Full Text] [Related]
7. Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective.
Simpson EL; Davis S; Thokala P; Breeze PR; Bryden P; Wong R
Pharmacoeconomics; 2015 Nov; 33(11):1187-94. PubMed ID: 26017401
[TBL] [Abstract][Full Text] [Related]
8. Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Bui CN; O'Day K; Flanders S; Oestreicher N; Francis P; Posta L; Popelar B; Tang H; Balk M
J Manag Care Spec Pharm; 2016 Feb; 22(2):163-70. PubMed ID: 27015255
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer.
Holko P; Kawalec P
Expert Rev Anticancer Ther; 2014 Jan; 14(1):63-73. PubMed ID: 24224852
[TBL] [Abstract][Full Text] [Related]
10. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
11. Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.
Massoudi M; Balk M; Yang H; Bui CN; Pandya BJ; Guo J; Song Y; Wu EQ; Brown B; Barlev A; Flanders S
J Med Econ; 2017 Feb; 20(2):121-128. PubMed ID: 27570999
[TBL] [Abstract][Full Text] [Related]
12. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
13. Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
Ramaekers BLT; Riemsma R; Tomini F; van Asselt T; Deshpande S; Duffy S; Armstrong N; Severens JL; Kleijnen J; Joore MA
Pharmacoeconomics; 2017 Feb; 35(2):191-202. PubMed ID: 27566699
[TBL] [Abstract][Full Text] [Related]
14. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
James N; Pirrie S; Pope A; Barton D; Andronis L; Goranitis I; Collins S; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Russell M; Billingham L
Health Technol Assess; 2016 Jul; 20(53):1-288. PubMed ID: 27434595
[TBL] [Abstract][Full Text] [Related]
15. The economics of abiraterone acetate for castration-resistant prostate cancer.
Dellis A; Papatsoris AG
Expert Rev Pharmacoecon Outcomes Res; 2014 Apr; 14(2):175-9. PubMed ID: 24564607
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients.
Ten Ham RMT; van Nuland M; Vreman RA; de Graaf LG; Rosing H; Bergman AM; Huitema ADR; Beijnen JH; Hövels AM
Value Health; 2021 Jan; 24(1):121-128. PubMed ID: 33431146
[TBL] [Abstract][Full Text] [Related]
17. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
[TBL] [Abstract][Full Text] [Related]
18. Economic Evaluations of Anticancer Drugs Based on Medico-Administrative Databases: A Systematic Literature Review.
Bouée-Benhamiche E; Bousquet PJ; Ghabri S
Appl Health Econ Health Policy; 2020 Aug; 18(4):491-508. PubMed ID: 32056121
[TBL] [Abstract][Full Text] [Related]
19. First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials.
Poorthuis MHF; Vernooij RWM; van Moorselaar RJA; de Reijke TM
BJU Int; 2017 Jun; 119(6):831-845. PubMed ID: 28063195
[TBL] [Abstract][Full Text] [Related]
20. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
Huxley N; Crathorne L; Varley-Campbell J; Tikhonova I; Snowsill T; Briscoe S; Peters J; Bond M; Napier M; Hoyle M
Health Technol Assess; 2017 Jun; 21(38):1-294. PubMed ID: 28682222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
